Aurobindo Pharma, a Rs.4,550 crore pharma major from Hyderabad, has posted consolidated net profit of Rs.222 crore during the second quarter ended September 2012 as against a net loss of Rs.80.16 crore mainly due to foreign exchange gain of Rs.117.67 crore during the current quarter as compared to a loss of Rs.185.12 crore. Its EBDITA went up by 113 per cent to Rs.256.87 crore from Rs.120.89 crore.
The company's net sales grew significantly by 41 per cent to Rs.1,481 crore from Rs.1,051 crore in the similar quarter of last year. Its domestic sales increased by 35.3 per cent to Rs.375.40 crore from Rs.277.20 crore and its exports increased by 50.4 per cent to Rs.1,048 crore from Rs.697 crore. The company's sales in US moved up 50 per cent to Rs.425 crore from Rs.283 crore and that in Europe increased by 82 per cent to Rs.226 crore from Rs.124 crore.
The company filed 17 ANDA in USA, taking cumulative filings to 265 ANDAs. Further, it filed 6 DMFs and its cumulative filing reached at 170. Following approvals, its cumulative approvals reached at 162 in USA, 34 in Australia and 23 in Canada during the second quarter ended September 2012.
Commenting on the performance, N Govindarajan, managing director, said, “We have witnessed strong performance during the quarter, recording healthy growth in our sales and earnings both sequentially and on a year on year basis. We are positive that our continued efforts to introduce new formulation products coupled with growing business of high value APIs in advanced markets will help sustain our operational and financial performance going forward.”
For the first half ended September 2012, Aurobindo clocked a net profit of Rs.93.44 crore as against a net loss of Rs.202.95 crore. The net loss in the previous period was mainly due to foreign exchange loss of Rs.182.24 crore and exceptional items (loss) of Rs.138.31 crore. The company's consolidated net sales increased by 26.6 per cent to Rs.2,678 crore from Rs.2,116 crore. Its EBDITA improved by 36.5 per cent to Rs.398.84 crore from Rs.292.11 crore in the same period of last year.